Sangivamycin
Appearance
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.162.068 |
Chemical and physical data | |
Formula | C12H15N5O5 |
Molar mass | 309.28 g·mol−1 |
3D model (JSmol) | |
| |
|
Sangivamycin is a natural product originally isolated from Streptomyces rimosus, which is a is a nucleoside analogue. It acts as an inhibitor of protein kinase C. It has antibiotic, antiviral and anti-cancer properties and has been investigated for various medical applications, though never approved for clinical use itself, however a number of related derivatives continue to be researched.[1][2][3][4][5][6][7]
See also
- CMX521 (methylated analogue)
- GS-441524
- NITD008
- Pyrazofurin
References
- ^ Tolman RL, Robins RK, Townsend LB (January 1968). "Pyrrolo[2,3-d]pyrimidine nucleoside antibiotics. Total synthesis and structure of toyocamycin, unamycin B, vengicide, antibiotic E-212, and Sangivamycin (BA-90912)". Journal of the American Chemical Society. 90 (2): 524–6. doi:10.1021/ja01004a076. PMID 5634627.
- ^ De Clercq E, Bernaerts R, Bergstrom DE, Robins MJ, Montgomery JA, Holy A (March 1986). "Antirhinovirus activity of purine nucleoside analogs". Antimicrobial Agents and Chemotherapy. 29 (3): 482–7. doi:10.1128/aac.29.3.482. PMID 3013084.
- ^ Loomis CR, Bell RM (February 1988). "Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C". The Journal of Biological Chemistry. 263 (4): 1682–92. PMID 3338987.
- ^ Kučić N, Mahmutefendić H, Lučin P (August 2005). "Inhibition of protein kinases C prevents murine cytomegalovirus replication". The Journal of General Virology. 86 (Pt 8): 2153–2161. doi:10.1099/vir.0.80733-0. PMID 16033962.
- ^ Lee SA, Jung M (May 2007). "The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation". The Journal of Biological Chemistry. 282 (20): 15271–83. doi:10.1074/jbc.M701362200. PMID 17371872.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ Bastea LI, Hollant LM, Döppler HR, Reid EM, Storz P (November 2019). "Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death". Scientific Reports. 9 (1): 16588. doi:10.1038/s41598-019-53223-0. PMID 31719634.
- ^ Smith HC, et al. Methods of treating and inhibiting ebola virus infection. Patent application CA3040540, Oyagen Inc, 17 May 2018